Immunotherapy Addition Demonstrates Sustained Survival Benefits in Long-Term Follow-Up of NRG Oncology Trial for Advanced or Recurrent Endometrial Cancer

In a groundbreaking advancement for the treatment of advanced and recurrent endometrial cancer, recent prolonged follow-up results from the NRG Oncology GY018 phase 3 trial have reinforced the survival benefits of incorporating pembrolizumab, an immunotherapy agent, alongside standard chemotherapy. Initially reported immature overall survival data had suggested a promising improvement, but with extended monitoring, these […]